Came across this in a 2010 post
elsewhere. My apologies if it's already been covered.
"ASCO/CAP guidelines recommend that HER2 status be determined for all invasive breast cancer patients. These guidelines caution that
current HER2 testing methods (central IHC and FISH) may be inaccurate in up to 20% of cases. HERmark Breast Cancer Assay precisely quantifies HER2 total protein and HER2 homodimer levels in FFPE. HERmark reclassified up to 25% of samples from a cohort of the FinHer Adjuvant Breast Cancer Study. It is not known whether there is a benefit to test by two modalities or not and HERmark is only one a panoply of next generation of HER tests that are available or coming the the market."
Threaded Mode